| Study (Reference) |
Population |
Regimen |
Result |
|
| ACTG 372b (4) |
N = 94 IDV-experienced, NNRTI-naive |
EFV + ADV + either (1) ABC + NFV (2) ABC (3) NRTIs + NFV (4) NRTIs |
NFV groups superior; 45% had VL <500 at 16 weeks. No difference between ABC and NRTIs. |
| ACTG 359 (6) |
N = 277 IDV-experienced, NNRTI-naive VL: 2,000-200,000 |
SQV/RTV or SQV/NFV + either (1) DLV (2) ADV (3) DLV + ADV |
DLV groups superior; 40% had VL<=500 at 16 weeks. No difference between SQV/RTV and SQV/NFV. |
| CNAA 2007 (7) |
N = 90 heavily treatment-experienced |
ABC + EFV + APV |
Overall, 26% had VL <400 at 16 weeks; in subgroup analysis, NNRTI-naive and baseline VL <40,000 were superior. |
| ACTG 373 (8) |
N = 54 APV-experienced (30 patients with VL <500) |
d4T + 3TC + NVP + IDV |
80% had VL <500 by 12 weeks, continuing for 60 weeks (on-treatment analysis). |
| ABT-765 (9) |
N = 70 PI-experienced, NNRTI-naive. VL: 1,000-100,000 |
ABT-378 + low dose RTV + 2 NRTIs + NVP |
77% had VL <400 at 24 weeks (intent-to-treat analysis). |
